ReviewNature medicine2019
Publisher Correction: The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.
Abstract readReviewPublished Erratum
In one paragraph
Review in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Quantitative molecular cartography of emergency myelopoiesis reveals conserved modules of hematopoietic activation.Cell stem cell · 2026Article
- Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia.Leukemia · 2024Article
- CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target.The Journal of clinical investigation · 2022Article
- Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.Journal of hematology & oncology · 2022Review
- Murine Models of Acute Myeloid Leukemia.Frontiers in oncology · 2022Review
- First case report of a NUP98-PMX1 rearrangement in de novo acute myeloid leukemia and literature review.BMC medical genomics · 2021Review
Corrections and comments
- Erratum for
Authors and funding
29 authors.
Hamid BolouriDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. hbolouri@fhcrc.org.
Jason E FarrarWinthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences and Arkansas Children's Research Institute, Little Rock, Arkansas, USA.
Timothy TricheJane Anne Nohl Division of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Rhonda E RiesClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Emilia L LimCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Todd A AlonzoKeck School of Medicine, University of Southern California, Los Angeles, California, USA.
Yussanne MaCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Richard MooreCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Marco A MarraCanada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Jinghui ZhangDivision of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Xiaotu MaDivision of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Yu LiuDivision of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Yanling LiuDivision of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Jaime M Guidry AuvilOffice of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
Tanja M DavidsenOffice of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
Patee GesuwanOffice of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
Leandro C HermidaOffice of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
Bodour SalhiaDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Stephen CaponeJane Anne Nohl Division of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Giridharan RamsinghJane Anne Nohl Division of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Christian Michel ZwaanDepartment of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Sanne NoortDepartment of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
Stephen R PiccoloDepartment of Biology, Brigham Young University, Provo, Utah, USA.
E Anders KolbNemours Center for Cancer and Blood Disorders, Alfred I. DuPont Hospital for Children, Wilmington, Delaware, USA.
Alan S GamisDivision of Hematology, Oncology and Bone Marrow Transplantation, Children's Mercy Hospitals and Clinics, Kansas City, Missouri, USA.
Malcolm A SmithCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA.
Daniela S GerhardOffice of Cancer Genomics, National Cancer Institute, Bethesda, Maryland, USA.
Soheil MeshinchiClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. smeshinc@fhcrc.org.
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MCOG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MChildren's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5MTranslational Regulation in Normal Erythropoiesis and Diamond Blackfan AnemiaP20GM121293 · NIGMS · ARKANSAS CHILDREN'S HOSPITAL RES INST · PI Samrat Roy Choudhury · 2017 to 2026
$27.6MSupport for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5MBiology/prognostic implications of Flt3 mutations in AMLR01CA114563 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MESHINCHI, SOHEIL · 2005 to 2016
$4.4MNCI NIH HHS HHSN261200800001ENCI NIH HHS R01 CA114563NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766NIGMS NIH HHS P20 GM121293
Abstract
In the version of this article originally published, the color key in Fig. 1a was wrong. In the Cytogenetics key, the box over t(8;21) originally was green. It should have been red, matching the color of the sections of the pie graphs below the key that were labeled with 15% and 19%.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.